#pharmaceutical

FDA Issues Third Warning to Novo Nordisk Over GLP-1 Drug Reporting Failures

The FDA's recent warning to Novo Nordisk highlights ongoing concerns regarding the company's reporting practices for GLP-1 drugs, particularly related to potential side effects.